ISA, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline

Grant accelerates clinical development of immunotherapy to treat chronic hepatitis B virus infection

Oegstgeest, 20 July 2021 – ISA Pharmaceuticals B.V. is pleased to announce that a consortium between the Erasmus MC and ISA has been awarded a Private-Public Partnerships (PPP) Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to conduct a first-in-human, phase 1 study of ISA104 to treat hepatitis B in chronically infected patients.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...